Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Biological Standardization

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0092-1157(89)90004-8PMID 2541133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of temperature on D-antigen and potency in chickens of inactivated poliomyelitis vaccines

  2005cited by this paper
• The use of guinea pigs in tests for immunogenic capacity of poliomyelitis virus preparations

  2005cited by this paper
• Evidence for conformational changes of poliovirus precursor particles during virus morphogenesis.

  1985cited by this paper
• Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.

  1985cited by this paper
• Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.

  1985cited by this paper
• A monoclonal antibody that neutralizes poliovirus by cross-linking virions

  1985cited by this paper
• Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.

  1984cited by this paper
• Oligosaccharide composition of calf rotavirus.

  1984cited by this paper
• One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine.

  1984cited by this paper
• Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization

  1983cited by this paper
• Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry.

  1983cited by this paper
• Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3

  1983cited by this paper
• Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies

  1983cited by this paper
• Evidence for several unrelated neutralization epitopes of poliovirus, type 1, strain Mahoney, provided by neutralization tests and quantitative enzyme-linked immunosorbent assay (ELISA).

  1983cited by this paper
• Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats.

  1982cited by this paper
• Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus 3.

  1982cited by this paper
• Potency testing of killed polio vaccine in rats.

  1981cited by this paper
• Potency testing of killed polio vaccine in rats.

  1981cited by this paper
• Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.

  1981cited by this paper
• Direct enzyme linked immunosorbent assay (ELISA) for quantification of poliomyelitis virus D-antigen.

  1980cited by this paper
• Immunoassay of poliovirus antigens by single-radial-diffusion: development and characteristics of a sensitive autoradiographic zone size enhancement (ZE) technique.

  1980cited by this paper
• Production of monoclonal antibodies: strategy and tactics.

  1980cited by this paper
• Intratypic serodifferentiation of poliomyelitis virus strains by strain-specific antisera.

  1979cited by this paper
• History of Sabin attenuated poliovirus oral live vaccine strains

  1973cited by this paper
• The in vitro determination of the D antigens of poliomyelitis viruses. I. The gel diffusion tes.

  1966cited by this paper
• An evaluation of the 1954 poliomyelitis vaccine trials.

  1955cited by this paper
• Suburbanization and suburbia.

  1955cited by this paper
• Isolation of a Non-Neurotropic Variant of Type I Poliomyelitis Virus

  1954cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation

  2025cites this paper
• Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines

  2025cites this paper
• Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particles

  2024cites this paper
• Discovery of a broad-spectrum monoclonal antibody recognizing a conserved, linear epitope WFYDGYPT on VP1 protein of Enterovirus A species

  2024cites this paper
• Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly

  2022cites this paper
• Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris

  2022cites this paper
• Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines

  2021cites this paper
• Characterization of Classical Vaccines by Charge Detection Mass Spectrometry.

  2021cites this paper
• Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines

  2021cites this paper
• Polio and Its Epidemiology

  2020cites this paper
• Comparative Molecular Biology Approaches for the Production of Poliovirus Virus-Like Particles Using Pichia pastoris

  2020cites this paper
• Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine.

  2020cites this paper
• Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine

  2019cites this paper
• Role of phenol red in the stabilization of the Sabin type 2 inactivated polio vaccine at various pH values

  2018cites this paper
• Plant-made polio type 3 stabilized VLPs—a candidate synthetic polio vaccine

  2017cites this paper
• Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines

  2017cites this paper
• Fabrication of fillable microparticles and other complex 3D microstructures

  2017cites this paper
• Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles

  2016cites this paper
• Transient expression of poliovirus-like particles in plants : developing a synthetic polio vaccine

  2016cites this paper
• New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication

  2015influential citation
• High resolution identity testing of inactivated poliovirus vaccines

  2015cites this paper
• Effect of formaldehyde inactivation on poliovirus 1 2

  2014cites this paper
• Effect of Formaldehyde Inactivation on Poliovirus

  2014influential citation
• Molecular characterisation of poliovirus inactivation with formaldehyde or other alternative chemical compounds

  2012cites this paper
• Repertoire of antibodies against type 1 poliovirus in human sera.

  2010cites this paper
• Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s.

  2008cites this paper
• Desenvolvimento de um Teste Imunoenzimático (ELISA) para a Detecção do Antígeno do Vírus da Febre Amarela (17DD) Inativado

  2007cites this paper
• Development of an enzyme immunoassay for poliovirus antigens

  2007cites this paper
• Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains.

  2003cites this paper
• Antigen quantification as in vitro alternative for potency testing of inactivated viral poultry vaccines

  2000cites this paper
• Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.

  1997cites this paper
• A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines.

  1995cites this paper
• Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine.

  1994cites this paper
• Conformation-dependent recognition of baculovirus-expressed Epstein-Barr virus gp350 by a panel of monoclonal antibodies.

  1993cites this paper
• Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.

  1993cites this paper
• Antigenic structure of poliovirus in inactivated vaccines.

  1993cites this paper
• In vitro potency assays for nonreplicating veterinary vaccines: comparison to in vivo assays and considerations in assay development.

  1993cites this paper
• Mapping of the epitopes of Epstein-Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants.

  1991influential citation
• Production of Poliovirus Vaccines: Past, Present, and Future

  1990cites this paper